Cervical & endometrial cancer
Oncology· 4 reviewed drugs· 28052 cited findings behind them
What the regulatory reviews cover
The drugs whose regulatory review documents appear in this library for Cervical & endometrial cancer include JEMPERLI and Tivdak. JEMPERLI is indicated for primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) in combination with carboplatin and paclitaxel. Tivdak is indicated for recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.
Different drugs were studied in different trials, so figures are not head-to-head. For JEMPERLI, the ORR was 9. For Tivdak, the median OS (months) was 11.7. Keytruda and Lenvima are also present in the library but their indications as stated in the reviews do not include Cervical & endometrial cancer.
The drugs — one cited result each
| Keytruda Merck & Co., Inc. | 24441 cited findings on the drug page → |
| JEMPERLI GSK plc | ORR: 9 GSK plc — Jemperli EMA EPAR variation assessment report (EME, p.38 |
| Lenvima Eisai Co., Ltd. | 584 cited findings on the drug page → |
| Tivdak Genmab A S | median OS (months): 11.7 Genmab A S — Tivdak EMA EPAR public assessment report (EMEA/, p.128 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.